Condensed Balance Sheets - USD ($)		Jun. 30, 2025	Dec. 31, 2024
Current assets:
Prepaid expenses		$ 1,200	$ 2,400
Total current assets		1,200	2,400
Deferred offering costs		95,569	22,817
Total Assets		96,769	25,217
Current liabilities:
Accrued expenses		32,171	30,070
Due to related party		57,922
Promissory note - related party		300,000	235,806
Total current liabilities		390,093	265,876
Total Liabilities		390,093	265,876
Commitments and Contingencies
Shareholder’s Deficit
Preferred shares, no par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2025 and December 31, 2024
Additional paid-in capital		25,000	25,000
Accumulated deficit		(318,324)	(265,659)
Total Shareholder’s Deficit		(293,324)	(240,659)
Total Liabilities and Shareholder’s Deficit		96,769	25,217
Class A Ordinary Shares
Shareholder’s Deficit
Ordinary shares
Class B Ordinary Shares
Shareholder’s Deficit
Ordinary shares	[1],[2]

[1] All share data has been retroactively presented. On November 9, 2022, 3,737,500 Class B ordinary shares were issued to the Sponsor for $25,000. On October 2, 2024, the Company issued 5,750,000 Class B ordinary shares to the Sponsor for $25,000, and immediately repurchased the 3,737,500 initial shares from the Sponsor for $25,000, resulting in 5,750,000 Class B ordinary shares outstanding after the repurchase. In May 2025, the Sponsor paid $25,000, or approximately $0.003 per share, in exchange for 7,666,667 founder shares (of which an aggregate of up to 1,000,000 shares are subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter) , and subsequently 5,750,000 of the founder shares were repurchased by the Company for an aggregate purchase price of $25,000 (See Note 5).

[2] Includes up to 1,000,000 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 5).